SCHEMBL23917445

SCHEMBL23917445

Cn1cc(-c2ccc(F)c(O)c2)c2c(N)ncnc21

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 13/20 0.57
PIK3CA P42336 12/20 0.57
PIK3CB P42338 12/20 0.57
PIK3CG P48736 12/20 0.57
PRKDC P78527 12/20 0.57
ABL1 P00519 11/20 0.57
EGFR P00533 11/20 0.57
HCK P08631 11/20 0.57
SRC P12931 11/20 0.57
KDR P35968 11/20 0.57
MTOR P42345 11/20 0.57
EPHB4 P54760 10/20 0.57
PI4KB Q9UBF8 7/20 0.57
EIF2AK3 Q9NZJ5 6/20 0.52
MET P08581 1/20 0.49
AXL P30530 1/20 0.49
BTK Q06187 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23917414 0.85 EIF2AK3 (0.49) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL20351783 0.85 RIPK2 (0.61) SRCEIF2AK3METAXL
SCHEMBL23917434 0.81 SRC (0.61) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL26110170 0.81 AXL (0.63) ABL1EGFRSRCKDREIF2AK3
SCHEMBL30582589 0.81 AXL (0.63) ABL1EGFRSRCKDREIF2AK3
SCHEMBL22434462 0.81 EIF2AK3 (0.50) EIF2AK3METAXL
SCHEMBL20351797 0.80 EIF2AK3 (0.48) ABL1EGFRSRCKDREIF2AK3
SCHEMBL13020096 0.79 SRC (0.69) ABL1EGFRHCKSRCKDR
SCHEMBL18874076 0.79 PIK3CD (0.56) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL25285654 0.78 NEK7 (0.56) EIF2AK3METAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210317140-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317140-A1 Heterocyclic Compounds and Methods of Use BTK, PIK3CD, PIK3CB PIK3CD 2/4885PIK3CA 6/4885PIK3CB 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.